The labeling approved for Effient by the Food and Drug Administration says not to use it in patients with prior strokes, a warning that is not present for Plavix.

The U.S. Food and Drug Administration approved the blood-thinning drug Effient on Friday in a long-awaited victory for its developers, Eli Lilly & Co. and Daiichi Sankyo Co. The drug, however ...

It's not revolutionary to suggest that the blockbuster drug model is ... Medco will then compare Plavix's efficacy in 14,000 of those selected patients to Effient in 14,000 other Medco members to ...

WASHINGTON -- The Food and Drug Administration on Friday approved a highly anticipated blood thinner from Eli Lilly, though the drug must carry the agency's sternest warning because of its ...

Now, analysts say they're no longer expecting the drug to be a blockbuster. "Even if the company isn't ready to give up on Effient, we are," a Goldman Sachs analyst writes to clients (as quoted by ...

It has been a long and at times bruising battle for Eli Lilly and Daiichi Sankyo (DSKYY.PK) to get US approval for their anti-blood clot drug, Effient, but on Friday, 19 months after first filing ...

The FDA just approved Effient, a blood thinner that will compete against the megablockbuster Plavix. The initial approval is for patients who undergo angioplasty (and typically get a stent) to ...